Evotec OAI to Provide Process Validation for AnorMED Inc. Phase III Compound, AMD 3100


Evotec OAI AG announced that AnorMED Inc has selected Evotec OAI to support AnorMED with the chemical development of its candidate AMD 3100, currently under evaluation in the clinic in stem cell mobilisation for stem cell transplantation in cancer patients. Using its integrated chemical and pharmaceutical development platform, EVOdevelop(TM), Evotec OAI will complete the full validation of the process to AMD 3100, including process research and development, analytical work and cGMP manufacturing, and will be responsible for producing the relevant CMC documentation for subsequent dossier filing.

Other news from the department business & finance

Most read news

More news from our other portals

Recognise, understand, heal: The World of Diagnostics